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The association of nonalcoholic fatty liver disease with
central and peripheral blood pressure in adolescence:
findings from a cross-sectional study
Sumaiya Patela, Debbie A. Lawlora,b, Diana L.S. Ferreiraa, Alun D. Hughesc, Nish Chaturvedic,
Mark Callawayd, Chris Daye, Naveed Sattarf, and Abigail Frasera,b
Objectives: We aimed to determine the association of
nonalcoholic fatty liver disease (NAFLD) with central and
peripheral blood pressure (BP), in a general adolescent
population and to examine whether associations are
independent of adiposity.
Methods: Using cross-sectional data from a subsample
(N¼1904) of a UK birth cohort, we assessed markers of
NAFLD including ultrasound scan (USS) determined fatty
liver, shear velocity (marker of liver fibrosis), alanine
aminotransferase (ALT), aspartate aminotransferase (AST)
and gamma-glutamyltransferase (GGT) at a mean age of
17.8 years. These were related to BP [central and
peripheral SBP and DBP and mean arterial pressure (MAP)].
Results: Fatty liver was positively associated with central
and peripheral SBP, DBP and MAP in models adjusting for
age, sex, social class, puberty and alcohol intake. These
positive associations were attenuated to the null when fat
mass was included. For example, in confounder-adjusted
models, not including fat mass, mean central SBP was
3.74mmHg [95% confidence interval (CI) 1.12 to 6.36]
higher in adolescents with USS fatty liver than in those
without; with additional adjustment for fat mass, the
association attenuated to the null value (0.37mmHg;
95% CI –3.09 to 2.36). Similar patterns were found for
associations of ALT and GGT with central and peripheral
BP. There was no consistent evidence of associations of
shear velocity or AST with BP measurements. Fatty liver
was not consistently associated with central pulse pressure
(PP), peripheral PP and Aix@75.
Conclusion: NAFLD is not associated with higher central
or peripheral BP in adolescents once confounding by
adiposity is taken into account.
Keywords: Avon Longitudinal Study of Parents and
Children, blood pressure, children, nonalcoholic fatty liver
disease, obesity
Abbreviations: Aix75, augmentation index at heart rate
75 beats per minute; CI, confidence interval; MAP, mean
arterial pressure; NAFLD, nonalcoholic fatty liver disease;
PP, pulse pressure; USS, ultrasound scan
INTRODUCTION
N
onalcoholic fatty liver disease (NAFLD) is the
accumulation of fat into the liver, in the absence
of excess alcohol intake and other established
causes [1]. NAFLD is associated with cardiovascular events
[2,3] and cardiovascular disease (CVD) is the leading cause
of death in people with NAFLD [2–4]. These observations
have led to investigations into the potential mechanisms
driving these association and there is now increasing
evidence that NAFLD is associated with greater carotid
intima-media thickness, a measure of atherosclerosis [5],
endothelial dysfunction [6,7], dyslipidemia [8,9], as well as
obesity, insulin resistance and diabetes [10], but the degree
to which some of these associations are independent of
other risk factors is not clear. In previous analyses using the
data used here, we have shown that ultrasound scan (USS)
determined NAFLD is associated with greater insulin resist-
ance and dyslipidemia, even after adjustment for dual-
energy X-ray absorptiometry (DEXA) determined total
body fat mass [11].
Elevated blood pressure (BP) in adulthood is a strong
determinant of cardiovascular risk [12,13]. BP tracks
through the life course with BP in childhood or adolescence
not only being associated with BP in adulthood [14,15] but
also with adult CVD independently of BP in later life [16].
Peripheral (i.e. brachial) BP is the most common measure-
ment taken, as it is easy to measure and a good predictor of
cardiovascular risk. However, central BP is more strongly
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related to vascular damage [17] and may be a better pre-
dictor of cardiovascular events than peripheral BP [18].
Evidence also suggests that the difference between central
BP and peripheral BP is more pronounced at younger ages
[19].
Several studies in adults have found positive associations
of NAFLD and higher liver enzymes with higher BP
[9,10,20–23]. Studying these associations in younger popu-
lations is informative, as potential confounding factors such
as smoking and use of medications affecting the liver,
including antihypertensive agents, are much less prevalent
than in adult populations.
The majority of studies examining the association of
NAFLD with BP in paediatric or adolescent populations
to date show that participants who are overweight/obese
with NAFLD (diagnosed by either biopsy, MRI or USS) have
higher BP than overweight/obese participants without
NAFLD [24–28]. However, there is little evidence about
these associations in the general adolescent population and
it is unknown whether association differs for central BP
compared with peripheral BP.
The aim of this study was to examine the association of
USS-determined and blood-based measures of NAFLD and
liver health with several central and peripheral BPmeasures
[central and peripheral SBP, DBP, mean arterial pressure
(MAP), central and peripheral pulse pressure (PP) and
augmentation index] in adolescents and to determine
whether any associations were explained by confounding
due to adiposity, which is strongly associated with both
NAFLD and BP.
MATERIALS ANDMETHODS
Study participants
The Avon Longitudinal Study of Parents and Children
(ALSPAC) is a prospective, population-based birth cohort
study that recruited 14 541 pregnancies, of which there
were 13 867 live births from 13,761 women in Avon, UK,
with expected dates of delivery 1 April 1991 to 31December
1992 (http://www.alspac.bris.ac.uk) [29,30]. The cohort has
been followed-up since birth with questionnaires and, from
the age of 7, participants have been seen regularly in clinic;
the most recent of these was the 17–18 year clinic assess-
ment. This clinic assessment was attended by 5206 partici-
pants and included two separate substudies. In one, liver
USS were conducted (N¼ 1935) and in the other, central
and peripheral BP measurements were taken (N¼ 3896).
To be eligible for the present study, participants had to have
participated in the liver USS substudy. Singletons, and one
randomly chosen twin from twin pairs, were included
(N¼ 1917). In order to remove any effect of fat accumu-
lation in the liver due to excess alcohol intake, consistent
harmful alcohol drinkers were removed from the analysis.
Information on participant’s alcohol consumption was
obtained using the Alcohol Use Disorders Identification
Tests questionnaire [31]. This was administered at 16 years,
and 17 years (at the same time as the USS assessment) and
participants were scored between 0 and 20 with a score
over 16 being classified as harmful alcohol consumption
[31]. Consistent harmful alcohol drinkers were defined by a
score of 16 or greater at both 16 and 17 years. After removal
of 13 participants classified as consistent harmful drinkers, a
sample of 1904 remained for the analysis.
Ethical approval for this study was obtained from the
ALSPAC Law and Ethics Committee and the Local National
Health Service Research Ethics Committee. All participants
provided written informed consent.
Liver ultrasound scans and blood-based
outcomes
For both the liver USS and all blood-based analyses, partici-
pants were fasted overnight for those attending clinic in the
morning, or for a minimum of 6 h, for those attending clinic
after lunch.
Liver ultrasound scans
A detailed description of the liver USS has been published
previously [11]. Briefly, upper abdominal USS was
completed by one of four trained sonographers using a
Siemens Acuson S2000 USS system, with the participant at
rest in the dorsal decubitus position. Echogenicity (amarker
of liver fat) was assessed during deep inspiration and
recorded as present, absent or uncertain according to
established protocols using the right kidney as the refer-
ence organ [32].
Acoustic radiation force impulse-imaging (ARFI) of the
right lobe of the liver was used to measure liver stiffness (or
fibrosis), using standard protocols [33,34] and this was used
as our main indicator of liver fibrosis. The right lobe of the
liver was viewed through the intercostal space such that the
pulse wave was traversing an area of at least 6 cm and was
not traversing any major vascular structures and the right
lobe was clearly viewed.
Shear velocity (in m/s) was assessed six times with a gap
of at least 1min between each measurement. The highest
and lowest of these measurements were excluded and the
Siemens Acuson S2000 system produced a mean of the
remaining four measurements. If this meanwas greater than
4m/s, a further six measurements were taken from the left
lobe. In the analyses, we have used the mean of four
measurements after the highest and lowest velocities (of
the six taken) were removed. When both right and left lobe
values were available, the lowest mean of the two has
been used.
Assessment of blood-based measures
Fasting blood samples were immediately spun and frozen at
–80oC. Measurements were assayed shortly (3–9 months)
after samples were taken with no previous freeze-thaw
cycles. All assays were completed in the same laboratory
at the University of Glasgow. ALT, GGT and AST were
measured by automated analyser with enzymatic methods.
Assessment of central and peripheral blood
pressure
Central BP and augmentation index was estimated using
applanation tonometry with a SphygmoCor Px Pulse Wave
Analysis System (Atcor Medical, NSW, Australia) at the
radial artery. Recordings were calibrated using the brachial
BP measured with the Omron 705 IT (Omron, The Nether-
lands) just prior to assessment of central pressure according
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to manufacturer instructions. Peripheral (brachial) BP was
measured in triplicate, using a validated automated device
(Omron 705 IT oscillometric BP monitor) using an appro-
priate size cuff, according to a standardized protocol. The
average of the last two measurements was used in analyses.
High SBP and DBP was defined using The Fourth Report
on the Diagnosis, Evaluation, and Treatment of High
Blood Pressure in Children and Adolescents [35]. MAP
was calculated from the calibrated radial pressure
waveforms. Augmentation pressure was calculated as
the difference between the second and the first systolic
shoulder of the central pressure wave curve, and the
augmentation index was expressed as the percentage of
augmentation from total PP. As the augmentation index is
influenced in an inverse and linear manner by heart
rate, augmentation index was normalized for a heart rate
of 75 beats per minute (bpm) to give the augmentation
index at 75 bpm (Aix@75). As it is unclear what the phys-
iological meaning of negative values of augmentation
index is [36], we also repeated the analysis with Aix@75,
restricting the sample to those participants whose
Aix@75 was at least 0.
Assessment of other variables
Parental occupation was used to derive household occu-
pational social class, with each household assigned the
highest parental occupational [classes I (professional/man-
agerial) to V (unskilled manual workers), using the 1991
British Office of Population and Census Statistics (OPCS)
classification]. The participant’s age was calculated in
months from their date of birth and date of attendance at
the clinic assessment. Offspring height was measured with-
out shoes to the nearest 0.1 cm using a Harpenden stadi-
ometer. A Lunar prodigy narrow fan beam densitometer
was used to perform a whole body DEXA scan from which
lean and fat mass were measured. Self-reported puberty
stage, based on the Tanner staging system, was collected at
age 17 by postal questionnaire. Pubertal stage was based on
pubic hair staging for male participants and pubic hair and
breast staging for female participants. If both were avail-
able, then the higher grade was used (taking the one
suggesting higher stage if pubic hair and breast staging
suggested different stages).
Statistical analysis
All analysis was conducted using Stata version 12.0 MP2
(Stata Inc., College Station, Texas, USA). A series of multi-
variable regression models were constructed in order to
examine the associations between measures of liver disease
and BP and to explore the impact of adjustment for poten-
tial confounding factors. In the basic model (model 1), we
controlled for age and sex. In the confounder-adjusted,
minus fat mass, model (model 2), we additionally adjusted
for household occupational social class, pubertal stage and
alcohol intake. In the full confounder adjusted (model 3),
we further adjusted for DEXA-assessed fat mass and
included height and height-squared as covariables to
remove any association of fat mass with height. In sensi-
tivity analyses, we examined whether adjustment for BMI
instead of DXA-assessed fat mass altered the associations
examined (model 3).
Dealing with missing data and additional
analyses
Of the 1904 eligible participants (those included in the liver
ultrasound study and not classed as consistent harmful
drinkers), a proportion had missing data on any of
exposures, outcomes and potential confounding factors
[extent of missing for any single variable varied from 0 to
44.3% (Supplementary web table S1, http://links.lww.com/
HJH/A439)]. To increase efficiency and minimize selection
bias, we used multivariate multiple imputation to impute
missing data for any of the eligible participants with missing
data. We included all exposures, covariables, outcomes and
potential predictors of missing data in the imputation. We
generated 40 imputed datasets that were combined by
Rubin’s rules [37].
We repeated the multivariable regression analyses in
complete cases (i.e. only including those participants
who were eligible and had no missing data on exposures,
covariables and outcomes) in order to compare the results
with the imputed analyses.
RESULTS
Table 1 summarizes the distribution of characteristics in the
observed data for the eligible sample (i.e. those participants
who had at least one USS measure and were not consistent
hazardous drinkers). The prevalence of USS-determined
fatty liver was 2.5%; no participants were classified as
‘uncertain’ with regard to the presence of fat in liver. The
mean difference between central and peripheral SBP was
19.9mmHg (SD¼ 4.8) Distributions of all variables were
similar in the multivariate imputation databases and the
observed data (see Supplementary web table S1, http://
links.lww.com/HJH/A439).
Table 2 summarizes the multivariable associations of
USS-determined fatty liver with measures of central and
peripheral BP using the multivariate multiple imputation
datasets. In the basic model (model 1), USS-determined
fatty liver was positively associated with central and
peripheral SBP, DBP and MAP. These associations atte-
nuated slightly but persisted in the confounder, minus
fat mass, adjusted model (model 2). Associations were
attenuated to the null value when we additionally
adjusted for confounding by fat mass (and height)
(model 3). There was no strong evidence of associations
of USS-determined fatty liver with central and peripheral
PP in any of the models, with weak evidence of inverse
associations upon adjustment for fat mass (model 3).
USS-determined fatty liver was positively associated
with augmentation index @75; however, the 95% confi-
dence interval (95% CI) included the null value in all
models.
Table 3 summarizes the multivariable associations of
shear velocity, ALT, AST and GGT with measures of central
and peripheral BP. Greater shear velocity (a marker of liver
fibrosis) was associated with higher central and peripheral
SBP in models 1 and 2, but associations were attenuated to
the null value and coefficients became negative upon
adjustment for fat mass (model 3). There was no strong
evidence of associations with DBP, MAP and central and
peripheral PP in any of the models.
Patel et al.
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Shear velocity was inversely associated with augmenta-
tion index @75 in all models. ALT and GGT were positively
associated with all BP outcomes in the basic and con-
founder-adjusted models (models 1 and 2, respectively),
although for augmentation index @75, the 95% CI spanned
the null value. These positive associations were attenuated
towards the null when fat mass was included in the model
(model 3). There was no evidence of an association
between AST and BP outcomes in any of the models.
Associations of USS-determined fatty liver, shear velocity
and blood-based markers of NAFLD with augmentation
index @75, restricted to those participants with values at
least 0 (N¼ 852), are presented in Supplementary web
table S2, http://links.lww.com/HJH/A439 for completion.
Markers of NAFLD were generally inversely associated with
augmentation index @75 at least 0, though CIs were wide
due to the reduced sample size.
There were no notable differences in the associations of
markers of NAFLD with BP outcomes when BMI was used
as a measure of adiposity, compared with using DXA-
assessed fat mass in model 3 (data not shown but available
on request).
Supplementary web tables S3 and S4, http://links.
lww.com/HJH/A439 show the multivariable associations
of USS-determined fatty liver, and shear velocity and
blood-based exposures, respectively, with measures of
BP in a complete case analysis, that is only including those
participants who were eligible and had no missing data on
any exposures, outcomes and confounders (N¼ 438).
Overall, results were similar to those presented here (using
the multivariate multiple-imputed datasets), in terms of the
direction of associations and how associations changed
upon adjustment for fat mass, although the magnitude of
the associations was larger, and CIs were wider due to the
reduced sample size. The association between USS-deter-
mined NAFLD and MAP followed this same pattern, but the
CI did not quite span the null value even when fully
adjusted (model 3).
Supplementary web tables S5 and S6, http://links.
lww.com/HJH/A439 show the multivariable associations
of USS-determined fatty liver, and shear velocity and
blood-based markers of NAFLD, respectively, with
measures of high BP. Participants with USS-determined
fatty liver, and with higher shear velocity, ALT, AST and
GGT had greater odds of high SBP. This association was
attenuated towards the null when adjusting for adiposity
(model 3). Higher ALT and AST was associated with greater
odds of high DBP and the same attenuation of the estimate
was observed when adjusting for adiposity; however, the
95% CIs included the null value for all the models.
DISCUSSION
In this study,we assessed liver health usingUSS to determine
the presence of fat in the liver, ARFI to determine shear
velocity (a marker of fibrosis) as well as measuring blood-
based markers namely ALT, AST and GGT. There were no
known cases of liver disease in this cohort and we removed
the small number of participants who had reported consist-
ent harmful drinking in the preceding 2 years. Therefore, it is
reasonable to assume that in our cohort, USS-determined
fatty liver is likely to represent NAFLD.
The aim of our study was firstly to examine the associ-
ations of NAFLD with central and peripheral BP and
secondly to consider whether these associations are con-
founded by adiposity. The results demonstrate that for USS-
determined NAFLD, ALT and GGT, there were positive
associations with central and peripheral SBP and DBP
and MAP. Interestingly, despite the large differences in
central SBP and peripheral SBP, associations of NAFLD
with both were of similar magnitude and CIs overlapped.
We also found that positive associations were confounded
by total body fat mass, with all attenuating towards the null
value when adjusting for it. In contrast to the positive
TABLE 1. Distribution of characteristics of the eligible sample
(i.e. participants who attended the 17-year clinic and
had at least one ultrasound scan measure)
Characteristic N
Distribution mean (SD)
for continuous variables
or % for categorical
variables
Male, % (N) 1904 41.5 (791)
Age (years) 1904 17.9 (0.4)
Manual social class, % (N) 1616 12.9 (209)
Postpuberty, % (N) 1059 82.7 (877)
Fat mass (kg), median (IQR) 1827 17.0 (11.4–24.0)
Truncal fat (g) median (IQR) 1819 8.4 (5.6–12.1)
BMI categories, % (N) 1847
Underweight 8.0 (147)
Normal 68.0 (1255)
Overweight 17.0 (313)
Obese 7.0 (132)
Height (cm), mean (SD) 1847 170.7 (9.4)
Smoker, % (N) 1188 10.3 (122)
Alcohol intake (AUDIT score),
% (N)
1704
0–7 61.4 (1047)
8–15 33.2 (566)
16þ 5.4 (92)
Heart rate (bpm), mean (SD) 1510 70.8 (10.8)
Ultrasound fatty liver, % (N) 1739 2.5 (43)
Shear velocity (m/s), median
(IQR)
1742 1.2 (1.1–1.3)
ALT (U/l), median (IQR) 1293 15.7 (12.5–20.1)
AST(U/l), median (IQR) 1293 19.8 (17.0–23.4)
GGT (U/l), median (IQR) 1292 16.0 (13.0–21.0)
Central SBP (mmHg),
mean (SD)
1512 96.0 (9.1)
Peripheral SBP (mmHg),
mean (SD)
1512 115.8 (11.6)
High peripheral SBP
(120mmHg), % (N)a
1512 7.6
DBP (mmHg), mean (SD) 1512 63.5 (7.4)
High DBP (80mmHg), % (N)a 1512 0.8
MAP (mmHg), mean (SD) 1512 79.7 (8.0)
Central pulse pressure (mmHg),
mean (SD)
1512 31.2 (6.6)
Peripheral pulse pressure
(mmHg), mean (SD)
1512 52.4 (10.4)
Augmentation index at heart
rate 75 bpm (%), mean (SD)
1486 1.5 (11.4)
Augmentation index at heart
rate 75 bpm with values
greater than 0 (%), mean (SD)
639 9.0 (6.6)
ALT, alanine aminotransferase; AST, aspartate aminotransferase; bpm, beats per minute;
GGT, gamma-glutamyltransferase: IQR, interquartile range; SD, standard deviation: MAP,
mean arterial pressur.
aBased on The Fourth Report on the Diagnosis, Evaluation and treatment of high Blood
Pressure in Children and Adolescents [35].
NAFLD and blood pressure in adolescents
Journal of Hypertension www.jhypertension.com 549
 Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
associations of USS-determined NAFLD with SBP and DBP
in the main confounder-adjusted model, there were only
weak associations with central PP and peripheral PP and
Aix@75. Associations with central PP and peripheral PP
became negative following adjustment for adiposity. PP
depends on stroke volume, arterial stiffness and wave
reflection [38]. In a study in this same cohort at a mean
age of 10.6 years, overweight and obese participants had
reduced arterial stiffness as measured by pulse wave
velocity compared with normal weight participants [39]
and a similar negative association between arterial stiffness
and adiposity has been reported until in middle age [40].
This may explain the inverse association seen with PP when
adjusting for adiposity.
TABLE 2. Multivariable associations [mean difference (95% confidence intervals)] of ultrasound scan determined fatty liver and with
measures of central and peripheral blood pressure and arterial stiffness (N¼1904)
USS-determined fatty liver (yes vs. no)
Mean difference (95% confidence intervals)
Model 1 Model 2 Model 3
Central SBP (mmHg) 3.92 (1.32 to 6.52) 3.74 (1.12 to 6.36) 0.37 (3.09 to 2.36)
Peripheral SBP (mmHg) 4.00 (0.87 to 7.14) 3.82 (0.67 to 6.97) 1.04 (4.34 to 2.26)
DBP (mmHg) 4.00 (1.73 to 6.27) 3.91 (1.62 to 6.20) 1.05 (1.33 to 3.42)
Mean arterial pressure (mmHg) 3.87 (1.42 to 6.32) 3.72 (1.24 to 6.20) 0.31 (2.29 to 2.90)
Central pulse pressure (mmHg) 0.33 (2.16 to 1.51) 0.41 (2.24 to 1.42) 1.74 (3.67 to 0.18)
Peripheral pulse pressure (mmHg) 0.00 (2.83 to 2.83) 0.09 (2.93 to 2.75) 2.09 (5.08 to 0.90)
Augmentation index at heart rate 75 bpm (%) 1.82 (1.76 to 5.39) 1.69 (1.91 to 5.30) 1.25 (2.53 to 5.03)
Model 1 (basic model): adjusted for age at time of assessment and sex. Model 2 (confounder-adjusted model minus fat mass): as model 1 and additionally adjusted for social class,
puberty and alcohol intake. Model 3 (adiposity-adjusted model): as model 2 and additionally adjusted for DEXA-assessed fat mass, height and height squared. bpm, beats per minute;
USS, ultrasound scan.
TABLE 3. Multivariable associations [mean difference (95% confidence intervals)] of shear velocity and blood-based markers of
nonalcoholic fatty liver disease with central and peripheral blood pressure measures (N¼1904)
Mean difference (95% confidence intervals)
Model 1 Model 2 Model 3
Central SBP (mmHg)
Shear velocity per SD (m/sec) 0.48 (0.06 to 0.90) 0.43 (0.01 to 0.85) 0.16 (0.58 to 0.27)
ALT per 10U/l 0.90 (0.45 to 1.35) 0.84 (0.39 to 1.29) 0.27 (0.19 to 0.73)
AST per 10U/l 0.34 (0.15 to 0.84) 0.34 (0.16 to 0.85) 0.12 (0.38 to 0.61)
GGT per 10U/l 1.66 (1.08 to 2.25) 1.59 (1.00 to 2.18) 0.96 (0.34 to 1.59)
Peripheral SBP (mmHg)
Shear velocity per SD (m/s) 0.63 (0.12 to 1.14) 0.59 (0.08 to 1.09) 0.09 (0.62 to 0.43)
ALT per 10U/l 1.22 (0.68 to 1.76) 1.18 (0.64 to 1.73) 0.54 (0.03 to 1.11)
AST per 10U/l 0.51 (0.11 to 1.13) 0.52 (0.10 to 1.14) 0.26 (0.35 to 0.86)
GGT per 10U/l 1.99 (1.30 to 2.68) 1.96 (1.26 to 2.65) 1.24 (0.50 to 1.99)
DBP (mmHg)
Shear velocity per SD (m/s) 0.25 (0.11 to 0.60) 0.22 (0.14 to 0.58) 0.22 (0.58 to 0.14)
ALT per 10U/l 0.61 (0.22 to 1.00) 0.57 (0.18 to 0.97) 0.15 (0.26 to 0.56)
AST per 10U/l 0.06 (0.40 to 0.51) 0.06 (0.40 to 0.51) 0.11 (0.56 to 0.34)
GGT per 10U/l 1.05 (0.55 to 1.55) 1.02 (0.51 to 1.52) 0.54 (0.00 to 1.07)
Mean arterial pressure (mmHg)
Shear velocity per SD (m/s) 0.20 (0.19 to 0.59) 0.16 (0.23 to 0.55) 0.37 (0.76 to 0.02)
ALT per 10U/l 0.75 (0.34 to 1.17) 0.70 (0.29 to 1.12) 0.20 (0.22 to 0.63)
AST per 10U/l 0.19 (0.29 to 0.67) 0.20 (0.28 to 0.68) 0.01 (0.48 to 0.47)
GGT per 10U/l 1.32 (0.79 to 1.85) 1.26 (0.72 to 1.80) 0.69 (0.13 to 1.25)
Central pulse pressure (mmHg)
Shear velocity per SD (m/s) 0.27 (0.03 to 0.57) 0.25 (0.05 to 0.55) 0.10 (0.22 to 0.41)
ALT per 10U/l 0.33 (0.00 to 0.65) 0.31 (0.01 to 0.62) 0.16 (0.19 to 0.51)
AST per 10U/l 0.29 (0.08 to 0.67) 0.30 (0.08 to 0.68) 0.24 (0.14 to 0.62)
GGT per 10U/l 0.62 (0.20 to 1.04) 0.58 (0.15 to 1.01) 0.43 (0.04 to 0.90)
Peripheral pulse pressure (mmHg)
Shear velocity per SD (m/s) 0.38 (0.07 to 0.84) 0.37 (0.09 to 0.82) 0.12 (0.34 to 0.61)
ALT per 10U/l 0.61 (0.12 to 1.10) 0.61 (0.11 to 1.10) 0.39 (0.14 to 0.92)
AST per 10U/l 0.45 (0.10 to 1.00) 0.46 (0.10 to 1.02) 0.37 (0.19 to 0.93)
GGT per 10U/l 0.94 (0.32 to 1.56) 0.94 (0.31 to 1.58) 0.71 (0.01 to 1.40)
Augmentation index at heart rate 75 bpm (%)
Shear velocity per SD (m/s) 0.52 (1.08 to 0.04) 0.57 (1.13 to 0.02) 0.73 (1.31 to 0.15)
ALT per 10U/l 0.24 (0.42 to 0.90) 0.17 (0.49 to 0.82) 0.05 (0.65 to 0.75)
AST per 10U/l 0.09 (0.82 to 0.63) 0.10 (0.82 to 0.62) 0.16 (0.89 to 0.56)
GGT per 10U/l 0.88 (0.00 to 1.76) 0.75 (0.15 to 1.64) 0.64 (0.31 to 1.60)
Model 1 (basic model): adjusted for age at time of assessment and sex. Model 2 (confounder-adjusted model): as model 1 and additionally adjusted for social class, puberty and alcohol
intake. Model 3 (adiposity-adjusted model): as model 2 and additionally adjusted for fat mass, height and height squared. ALT, alanine aminotransferase; AST, aspartate
aminotransferase; GGT, gamma-glutamyltransferase.
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Most previous studies that have reported the association
of NAFLD with BP in children or adolescents have been in
clinical populations who are overweight or obese [24–28].
Two studies in general (non-clinical) adolescents found
higher BP in participants with USS-determined NAFLD than
in those without NAFLD [41,42]. However, as the main
endpoint of these studies was not BP, multivariable analysis
was not conducted and hence whether this association was
confounded by adiposity was not examined. Interestingly,
using data from the Framingham Heart Study, Speliotes
et al. [9] reported that adults with NAFLD (assessed using X-
ray computed tomography) (N¼ 439) had higher SBP and a
greater prevalence of hypertension than adults without
NAFLD (N¼ 2150). However, as here, when adjusting for
BMI, waist circumference and visceral adipose tissue (or
adiposity traits), the association of NAFLD with SBP was
attenuated, but the association with hypertension
remained. Authors concluded that the association of NAFLD
with BP may be due to confounding by adiposity.
In a separate publication based on this same cohort [11],
we demonstrated that total and truncal fat mass are strongly
associated with USS-determined NAFLD. We also found
that associations of NAFLD with fasting glucose, insulin or
adverse levels of lipids were somewhat but not fully atte-
nuated upon adjustment for these adiposity measures (or
BMI) [11]. By contrast, the results of our current study
suggest that fat mass does fully confound the association
of NAFLD with BP. These results suggest that the observed
associations of NAFLD with CVD in adults may be due to
NAFLD being a causal risk factor for adverse glucose,
insulin and lipid concentrations and its effect on these,
but not on BP. That said, it is still unclear whether NAFLD is
a consequence and not a cause of insulin resistance, hyper-
glycaemia and dyslipidaemia. Alternatively, it is possible
that any potential effect of NAFLD on BP is cumulative and
will arise over time at a later age. As both the current study,
and our previous study [11], were cross-sectional, we are
unable to explore this further currently, though with further
follow-up of this cohort, we hope to do so.
In our study, we have used several markers of liver
health such as shear velocity (a marker of liver stiffness/
fibrosis) and blood-based markers. Results were consistent
across these, with the exception of AST that was not
associated with BP in any of the models. This may be
because AST is found in other organs such as muscle
and as such is a less specific marker of liver fat levels than
ALT and GGT [43,44].
Strengths and limitations
The key strength of this study is that it is a large general
adolescent population with several markers of NAFLD.
Although we acknowledge that the number of participants
with USS-determined NAFLD in our cohort is not large, we
also have continuous markers of NAFLD that provide
greater statistical power to detect associations and found
that the results were generally consistent across these. We
were able to consider both peripheral and central BP. The
latter has been shown to be more strongly associated with
CVD, and to our knowledge, the availability of central BP
measures is unique to our study. USS-determined NAFLD is
not the gold standard; however, liver biopsy would be
neither ethical nor feasible to conduct in a large healthy
population. Other methods such as MRI, although deemed
a better imaging method, are much costlier and computed
tomography (CT) scans are X-ray based and hence risk
exposing a healthy young population to radiation. We were
unable to adjust for physical activity or diet at age 17 years
as a possible confounder, as these measures were unavail-
able. However, considering the attenuation of the associ-
ations seen when for adjusting for adiposity (i.e. the
association is explained by confounding by adiposity), it
is unlikely that including physical activity or dietary intake
as confounders would have altered the interpretation of the
results. Our study is cross-sectional, and therefore, we
cannot assess causal effects or whether associations of
NAFLD in adolescencewith BP arise over time. Themajority
of this population are of European origin and we cannot
assume that results generalize to other populations.
Perspectives
In summary, in our cross-sectional analysis of a large
adolescent cohort, markers of NAFLD were associated with
greater central and peripheral BP, but these associations
were fully confounded by, and therefore explained by, fat
mass. These findings suggest that focusing on reducing
general overweight/obesity in adolescents to help prevent
future hypertension and its associated CVD risk is more
important than a specific focus on NAFLD.
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Reviewers’ Summary Evaluations
Reviewer 1
The study suggests that the effect of non-alcoholic fatty liver
disease (NAFLD) on blood pressure (BP) is only mediated
by adiposity. The finding is interesting because other
studies on the same issue, performed in populations of
overweight and obese subjects, had obtained different
results. A strength of the study is that in this case a popu-
lation-based group of adolescents and young adults, par-
ticipating in a prospective birth cohort study, was analysed.
However, in the examined population the proportion of
subjects with NAFLD was very low (2.5%) and this makes it
quite difficult to investigate the association between NAFLD
and BP. Moreover, it seems difficult to explain how, at the
same obesity level, a subject with fatty liver can have the
samemetabolic conditions and the same cardiovascular risk
as a subject without fatty liver. Other studies are necessary
to better understand this important issue.
Reviewer 2
The authors studied the relationship between NAFLD and
several blood pressure-related measures. The strengths of
this study are the use of ultrasound as well biochemical data
to determine the presence of NAFLD, the analysis of a
population-based sample, and the use of DEXA scans to
thoroughly determine body composition. The prevalence
of 2.5% NAFLD cases resulted in small number of subjects
analyzed in group comparisons. This weak point is bal-
anced by the generalizability of the findings. Overall, the
association of NAFLD with blood pressure measures is
completely dependent on body composition and annulled
when this confounder is properly considered.
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